Illumina - ILMN Stock Forecast, Price & News

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.

Analysts Set New Price Targets

ILMN has been the subject of a number of recent analyst reports. Piper Sandler decreased their price objective on Illumina from $360.00 to $320.00 and set an "overweight" rating for the company in a report on Friday. Robert W. Baird reduced their target price on Illumina from $306.00 to $215.00 in a report on Friday. Barclays lowered Illumina from an "equal weight" rating to an "underweight" rating and cut their price objective for the stock from $350.00 to $150.00 in a report on Wednesday, July 13th. Cowen cut their price objective on Illumina from $506.00 to $492.00 in a report on Friday, May 6th. Finally, SVB Leerink lowered their target price on shares of Illumina from $225.00 to $220.00 and set a "market perform" rating on the stock in a research report on Friday. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $284.45.

Illumina Price Performance

Shares of NASDAQ:ILMN traded up $19.09 during trading on Monday, reaching $227.41. The stock had a trading volume of 58,763 shares, compared to its average volume of 1,190,382. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.00 and a quick ratio of 0.82. The business's 50-day moving average price is $201.93 and its 200 day moving average price is $273.39. Illumina has a 52 week low of $173.45 and a 52 week high of $526.00. The stock has a market capitalization of $35.73 billion, a PE ratio of -3,772.37, a P/E/G ratio of 1.65 and a beta of 1.15.

Illumina (NASDAQ:ILMN - Get Rating) last announced its earnings results on Thursday, August 11th. The life sciences company reported $0.57 earnings per share for the quarter, missing analysts' consensus estimates of $0.63 by ($0.06). Illumina had a positive return on equity of 5.61% and a negative net margin of 0.43%. The company had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.22 billion. During the same period in the previous year, the company posted $1.87 earnings per share. Illumina's revenue for the quarter was up 3.2% on a year-over-year basis. As a group, equities analysts predict that Illumina will post 4.06 earnings per share for the current year.

Insider Activity at Illumina

In other Illumina news, SVP Alexander Aravanis sold 539 shares of the firm's stock in a transaction on Thursday, July 7th. The shares were sold at an average price of $200.00, for a total value of $107,800.00. Following the completion of the sale, the senior vice president now directly owns 3,346 shares in the company, valued at $669,200. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Illumina news, SVP Susan H. Tousi sold 250 shares of the stock in a transaction on Friday, June 10th. The shares were sold at an average price of $214.85, for a total transaction of $53,712.50. Following the completion of the sale, the senior vice president now owns 41,833 shares of the company's stock, valued at approximately $8,987,820.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Alexander Aravanis sold 539 shares of the stock in a transaction on Thursday, July 7th. The shares were sold at an average price of $200.00, for a total transaction of $107,800.00. Following the sale, the senior vice president now directly owns 3,346 shares of the company's stock, valued at approximately $669,200. The disclosure for this sale can be found here. 0.13% of the stock is owned by insiders.